Am J Cardiol. 1991;68:585 92. 81. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545 9. 82. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759 66. 83. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late throm- bolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342:767 72. 84 Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation. 1993;87:38 52. 85. Barrabes JA, Figueras J, Moure C, et al. Prognostic value of lead aVR in patients with a first non-ST-segment elevation acute myocardial infarction. Circulation. 2003;108:814 19. 86. de Winter RJ, Verouden NJ, Wellens HJ, et al. A new ECG sign of proxi- mal LAD occlusion. N Engl J Med. 2008;359:2071 3. 87. Jong GP, Ma T, Chou P, et al. Reciprocal changes in 12-lead electrocardi- ography can predict left main coronary artery lesion in patients with acute myocardial infarction. Int Heart J. 2006;47:13 20. 88. French JK, Feldman HA, Assmann SF, et al. Influence of thrombo- lytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J. 2003;146:804 10. 89. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clini- cal score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031 7. 90. The Global Use of Strategies to Open Occluded CoronaryArteries inAcute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. 